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ess: searsm@mcmaster.Summary The b-adrenoceptor agonists (b-agonists) have been used to relieve
bronchoconstriction for at least 5000 years. b-agonists are based on adrenaline and
early forms, such as isoprenaline, lacked bronchial selectivity and had unpleasant
side effects. Modern b-agonists are more selective for the b2-adrenoceptors (b2-
receptors) located in bronchial smooth muscle and have less cardiotoxicity.
Traditional b2-adrenoceptor agonists (b2-agonists), such as salbutamol, terbutaline
and fenoterol, were characterised by a rapid onset but relatively short duration of
action. While valuable as reliever medication, their short duration gave inadequate
night-time relief and limited protection from exercise-induced bronchoconstriction.
b2-agonists with longer durations of action, formoterol and salmeterol, were
subsequently discovered or developed. When combined with inhaled corticosteroids
they improved lung function, and reduced symptoms and exacerbations more than
an increased dose of corticosteroids. However, tolerance to the bronchprotective
effects of long-acting b2-agonists and cross-tolerance to the bronchodilator effects
of short-acting b2-agonists is apparent despite use of inhaled corticosteroids. The
role of b2-receptor polymorphisms in the development of tolerance has yet to be
fully determined.
Formoterol is unique in having both a long-lasting bronchodilator effect ð412 hÞ
and a fast onset of action (1–3min from inhalation), making it effective both as
maintenance and reliever medication. The recent change in classification from
short- and long-acting b2-agonists to rapid-acting and/or long-acting agents reflects
the ongoing evolution of b2-agonist therapy.
r 2004 Elsevier Ltd. All rights reserved.4 Elsevier Ltd. All rights reserved.
-522-1155x3286; fax: +1-905-521-6132.
ca (M.R. Sears).
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Asthma is a serious public health problem, being
one of the most common diseases in industrialised
countries. There is convincing evidence that the
prevalence and morbidity of asthma are increas-
ing.1,2 In the USA, 14 million adults and 5.2 million
children were affected by asthma in the mid-
1990s—an increase from the 1980 figures of 6.7
million and 4 million, respectively.3 Costs related to
asthma were estimated to reach $14.5 billion in the
USA by the year 2000.3 1ncreases such as these
have led to greater awareness of the importance of
patient and physician education—especially re-
garding the risk factors for asthma and the
treatment strategies available.
Since inflammation of the airway tissues is
considered to be the main mechanism in the
development and maintenance of asthma, limiting
exposure to inflammatory triggers and reducing the
inflammatory process using anti-inflammatory
drugs are the main thrusts of the modern manage-
ment of asthma.4,5 The first-line anti-inflammatory
drugs, inhaled corticosteroids (ICS), may be ade-
quate to fully control symptoms in mild cases.
However, for many patients, additional drug ther-
apy, typically bronchodilators that relax airway
smooth muscle, is needed for the relief of acute
symptoms.6 b2-adrenoceptor agonist bronchodila-
tors ðb2-agonists) are the most effective and widely
used drugs to produce rapid reversal of broncho-
constriction. Although traditionally classified by
their duration of action, as short-acting and long-
acting b2-agonists, such classifications may not now
reflect the full therapeutic relevance of these
agents.
b-adrenoceptor agonists (b-agonists), one of
the oldest classes of drugs used in medicine,
act by mimicking the effects of adrenaline.
Sympathomimetic agents were used in Chinese
herbal medicines to relieve breathing difficulties
as early as 3000 BC. The active material, an
alkaloid now identified as ephedrine, was originally
extracted from the plant Ephedra equisetina and
known as Ma Huang.7 However, ephedrine was only
introduced into western medicine as recently as
1924.8 The b2-agonists have become standard
bronchodilators for emergency room treatment of
asthma, and as day-to-day reliever medication.
Their role in maintenance treatment to control
asthma in conjunction with other medications,
particularly ICS, has been re-evaluated over the
past decade. This paper is a non-systematic review
of the evolution of b-agonists and provides a
perspective on their current role in the manage-
ment of asthma.Development of non-selective b-agonists
Adrenaline
Modern sympathomimetic drugs derive from the
discovery of a bronchodilating ‘adrenal substance’
by Solis-Cohen in 19009 and the joint isolation of
the active agent, adrenaline, by John Abel in 1899
and by Jokichi Takamine in 1901. By relaxing
bronchial smooth muscle, in preparation for the
increased ventilation needed for ‘flight or fight’,
endogenous adrenaline offers a potent and fo-
cussed treatment for the breathing difficulties
associated with asthma.
Adrenaline (epinephrine; Fig. 1)10 was initially
given parenterally, then by aerosol, and was widely
used in the treatment of asthma for at least 35
years following its discovery. However, although
inhaled adrenaline gave patients rapid relief of
asthma symptoms, concerns arose about possible
cardiotoxicity and the development of tolerance.11
The overuse of nebulised adrenaline spray that
resulted from tolerance was linked with a fivefold
increase in mortality in patients with asthma who
used the spray compared with non-users.11 Thus,
there was a need for drugs with the bronchodilating
effect of adrenaline but which had greater selec-
tivity for airway smooth muscle and correspond-
ingly fewer side effects.Isoprenaline
The first pure b-agonist to be synthesised was
isoprenaline (isoproterenol; Fig. 1), developed in
the 1940s. Although an effective bronchodilator
and more selective than adrenaline,12 isoprenaline
was still associated with substantial extra-pulmon-
ary side effects, such as palpitations, tachycardia
and headache. Isoprenaline, like adrenaline, is a
catecholamine, a class of drugs characterised by
chemical and metabolic instability resulting in a
short duration of action.13
The discovery that adrenaline and isoprenaline
had different physiological properties led to a
greater understanding of the nature of their
specificity and allowed more selective drugs to be
developed. Ahlquist14 noted that adrenaline was
more potent than isoprenaline in smooth muscle
that responded by contraction, but the opposite
was true in smooth muscle that responded by
relaxation. He suggested that tissues contained
different types of adrenergic receptors and that
the two drugs demonstrated different properties by
acting as agonists at these different receptors. This
initial classification introduced the concept of
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Figure 1 Chemical structure of selected b-agonists.10 Reproduced with kind permission from the Australian Medical
Association.
M.R. Sears, J. Lo¨tvall154alpha-(a) and beta-(b) adrenoceptors, with a-
receptors associated with vasoconstriction, stimu-
lation of the uterus and intestinal relaxation, and
b-receptors with vasodilation, bronchodilation and
myocardial stimulation.
Although adrenaline had both a- and b-receptor
agonist activity, isoprenaline had only b-receptor
agonist properties. However, although this ac-
counted for the different side-effect profiles of
the two drugs, explaining why some of the side
effects (such as urinary retention and hyperten-
sion) were associated only with adrenaline, it did
not explain the undesirable side effects of iso-
prenaline.
An analogue of isoprenaline, isoetharine (1951),
showed increased bronchodilator selectivity and
duration of effect, but still had undesirable cardiac
side effects. Only with the discovery that there was
more than one type of b-receptor15 did greater
selectivity become possible. The b1-receptor wasidentified in the heart and intestinal smooth
muscle, while the b2-receptor was identified
primarily in bronchial, vascular and uterine smooth
muscle. Isoprenaline was a non-selective b-agonist
(no a-receptor activity but activity at both b1- and
b2-receptors), which explained its side-effect
profile. Isoetharine improved the benefit-to-risk
ratio as a result of low a-receptor activity and
enhanced b2-receptor activity, as did the more
potent and longer-acting resorcinol analogue orci-
prenaline (metaproterenol) introduced in the early
1970s. However, both isoetharine and metaproter-
enol had undesirable cardiac side effects due to
action on b1-receptors. Furthermore, the presence
of a significant population of b2-receptors in
cardiac muscle meant that some cardiac stimula-
tion was inevitable even with a totally selective b2-
agonist.16 Use of small, inhaled doses of highly
selective b2-agonists was expected to result in
preferential activation of pulmonary b2-receptors,
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the systemic circulation and peripheral tissues.17
However, to target drugs more effectively, more
needed to be known about the b2-receptor and its
mechanism of activation.The b2-receptor
The b-receptor is a glycoprotein embedded in the
plasma membranes of a number of cell types. Three
distinct subtypes of b-receptors are now known, b1;
b2; b3; found predominately in cardiac muscle,
airway smooth muscle and adipose tissue, respec-
tively.18 The b2-receptor is composed of 413 amino
acid residues arranged in seven membrane-span-
ning alpha-helices.19 These helices form a three-
dimensional binding site accessible via the extra-
cellular aqueous biophase.20 Approximately 80% of
the b-receptors in the lungs are of the b2-
subtype.21 However, there is a homology of 54%
between the human b1- and b2-subtypes,
22 which
may result in any highly selective b2-agonist having
an effect on b1-receptors.
Ninety percent of the b2-receptors in the lungs
are thought to be located in the alveolar wall,23
with the remainder found on smooth muscle cells
and in the membranes of epithelial, endothelial
and mast cells.24 Smooth muscle cells may each
contain 30 000–40 000 b2-receptors.
25 No difference
has been reported in the number of receptors found
in healthy subjects and those with asthma,
although an inverse relationship has been reported
between lung b2-receptor density and forced
expiratory volume in 1 s (FEV1) (% predicted).
25 Of
relevance to the occurrence of cardiac side effects,
however, is that up to 40% of b-receptors in the
ventricles and up to 55% in the atria are also of the
b2-subtype.
26b-receptor activation
b-receptor activation increases levels of intracel-
lular cyclic adenosine monophosphate (cAMP) via
G-protein activation of adenyl cyclase.27 The cAMP
is then thought to influence key regulatory proteins
(cAMP-dependent protein kinases) involved in the
control of muscle tone, inhibit calcium ion release
from intracellular stores, reduce calcium ion entry
into the cells, and sequester intracellular calcium
ions.17 The result is to bring about relaxation of the
central and peripheral airway smooth muscle and
hence bronchodilation. Prolonged receptor binding
may however lead to desensitisation through
uncoupling or sequestration28,29 and may interferewith the action of other ligands,30 possibly due to
continued receptor occupation.
Ligands bind within the hydrophobic core of the
receptor, with critical interactions taking place
between chemical groups of the agonist and certain
key residues.24 The three-dimensional arrangement
of these interacting chemical groups has implica-
tions for structural changes resulting from poly-
morphisms in the receptor, and may also influence
the development of tachyphylaxis.b-receptor polymorphisms
The gene encoding the human b2-receptor is a gene
without introns, located on the long arm of
chromosome 5, and has a coding block of 1239
nucleotides.31–33 Nine variations occur in the
normal population.31,32,34 These polymorphisms
are point mutations distributed throughout the
coding block and are found at nucleotide positions
46, 79, 100, 252, 491, 523, 1053, 1098 and 1239.34
Five are degenerate and the remaining four, at
nucleotides 46, 79, 100 and 491, result in single
amino acid substitutions at positions 16 (arginine to
glycine), 27 (glutamine to glutamate), 34 (valine to
methionine) and 164 (threonine to isoleucine)33,34
(Fig. 2). Amino acids 16 and 27 lie in the
extracellular N-terminal domain while 34 and 164
are in the transmembrane spanning regions.33
The most common polymorphisms are at amino
acid positions 16 and 27 whereas that at 34 is rare,
with an allele frequency of o1%:32,35 The poly-
morphism at 164 is uncommon, the heterozygous
state having been found in only 3–5% of the
population.32,35 The frequency of the position 16
and 27 variants differs among white, black and
Asian populations.32,36 AII these polymorphisms
have been found with equal frequency in both
healthy individuals and patients with asthma and
are thus unlikely to be the cause of asthma per se.
However, they may influence the phenotype of the
illness once it is expressed,33 by acting as disease
modifiers, altering baseline airway function or the
response to b2-agonists.
35
The cellular phenotypes of these polymorphisms
are shown in Table 1. The Ile164 variant shows
altered agonist binding and altered receptor down-
regulation following agonist simulation.37 Gly16
and Gln27 are associated with increased down-
regulation following agonist exposure, while Glu27
appears to be protective against downregulation.
Several studies have shown an association between
polymorphisms 16 and 27 and airway responsive-
ness. Hall et al.38 showed that patients with asthma
who were homozygous for Glu27 had less reactive
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Figure 2 Primary amino acid sequence and proposed membrane topography of the human b2-receptor. Reprinted with
permission from Blackwell Publishing.34
Table 1 Cellular phenotypes of b2-adrenoceptor polymorphisms as determined in cell and transgenic systems.
Reprinted with permission from the American Academy of Allergy Asthma and Immunology.35
Nucleic acid no. Amino acid no. Designation Phenotype
46 16 Arg16 Wild type
46 16 Gly16 Enhanced downregulation
79 27 Gln27 Wild type
79 27 Glu27 Absent downregulation
100 34 Val34 Wild type
100 34 Met34 Normal
491 164 Thr164 Wild type
491 164 Ile164 Decreased coupling, binding and sequestration
M.R. Sears, J. Lo¨tvall156airways than those who were homozygous for
Gln27, showing a fourfold higher geometric mean
methacholine PD20 (provocative dose causing a 20%
fall in FEV1). Ramsay et al.
39 also found an
association between Glu27 and decreased airway
responsiveness to histamine. ln addition, Arg16 was
associated with increased wheeze during respira-
tory infection.39Kotani et al. showed that patients with asthma
homozygous for Gly16 had significantly ðPo0:05Þ
lower airway responsiveness to inhaled salbutamol
than those heterozygous for Arg/Gly16 or homo-
zygous for Arg16, and that those heterozygous
for Gln/Glu27 had a significantly ðPo0:05Þ later
onset of asthma than those with the wild-type
genes.40 Similarly, Lima et al.41 showed that Arg16
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lator response to salbutamol: patients homozygous
for Arg16 had a more rapid increase in FEV1 and a
higher bronchodilator response 1 h after salbutamol
administration than patients with the Gly16 allele.
In a study of 23 patients with nocturnal asthma and
22 patients with non-nocturnal asthma, the fre-
quency of the Gly16 allele was 80% in the noctural
group and 52% in the non-nocturnal group ðP ¼
0:007Þ with an odds ratio of 3.8 for having nocturnal
asthma and the Gly16 allele.42
Hancox et al.43 found no association between b2-
receptor polymorphism and the deleterious re-
sponse to long-term, regular fenoterol treatment.
In addition, Lipworth et al.44–46 showed in a number
of studies that polymorphism at codon 16 or 27 did
not influence the degree of functional antagonism
exhibited by formoterol, salmeterol or terbutaline.
In contrast, Taylor et al.47 found that among
patients homozygous for Arg16, the frequency of
major exacerbations more than doubled during
treatment with salbutamol compared with placebo
and that the rate of exacerbations during salbuta-
mol treatment was five times greater than among
homozygous Gly16 patients. Israel et al.48 also
showed that polymorphism at codon 16 had an
effect on the response to the regular use of
salbutamol: patients homozygous for Arg16 showed
a decline in morning peak expiratory flow (PEF)
while those homozygous for Gly16 did not.
The Gly16 polymorphism may also determine
patient susceptibility to bronchodilator desensiti-
sation. Tan et al.49 demonstrated a significantly
ðPo0:05Þ greater degree of bronchodilator desen-
sitisation following treatment with formoterol in
patients homozygous for Gly16 than in patients
homozygous for Arg16. Conversely, Lee et al.50
indicated that the Arg16 polymorphism was asso-
ciated with subsensitivity of response for bronch-
oprotection in patients taking regular ICS. This
subsensitivity was greater for formoterol than for
salmeterol.50 The different responses to formoterol
and salmeterol may reflect differences in intrinsic
receptor efficacy with regard to prolonged receptor
occupancy.
Subsensitivity may also be influenced by endogen-
ous catecholamines and their effect on basal b2-
receptor regulation. Liggett35 suggested two possi-
ble models of receptor kinetics. The dynamic model
indicated that the glycine form of b2-receptor would
be more susceptible to downregulation by endogen-
ous catecholamines, whereas the arginine form
would show basal upregulation, resulting in toler-
ance and subsensitivity upon b2-agonist exposure.
The alternate, static model suggests little or no
effect of endogenous catecholamines, resulting inthe glycine b2-receptor form being more susceptible
to downregulation and the arginine form less
susceptible when exposed to exogenous b2-agonists.
Jackson and Lipworth51 performed a retrospective
analysis of data from six placebo-controlled, rando-
mised, cross-over studies in an attempt to resolve
which model is applicable in patients. Their results
support the dynamic model, since Arg16 polymorph-
isms were associated with a subsensitivity of
response to long-acting b2-agonists.
Although point mutations clearly influence re-
sponse to b2-agonists, the effects of combinations
of mutations into complex haplotypes must also be
considered. Drysdale et al.52 investigated response
to salbutamol in 121 patients with asthma. Twelve
different haplotypes were expressed within the
group. For the five most common in vivo, b2-agonist
response was significantly related to the patients’
genotype ðP ¼ 0:007Þ: Haplotype pair 4/6 showed
the greatest increase in FEV1 while 4/4 showed the
smallest response. A similar study, however,
showed no significant effect of haplotype on the
in vivo response to isoprenaline.53
The exact clinical implication of different poly-
morphisms of the b2-receptor, and their impact on
acute or regular treatment with b2-agonists, is not
yet fully elucidated. Further prospective and
detailed studies of short- and long-acting b2-
agonists in large patient groups with different
receptor genotypes are needed.Development of more selective b2-agonists
The total effect of any b2-agonist involved in
bronchodilation is a property of its b2-receptor
binding affinity and its ability to induce an
intracellular response. The latter is due to a
conformational change in the receptor leading, in
turn, to one or more intracellular events. The
potency of a drug is related to the amount required
for a physiological response, whereas efficacy is a
term related to the drug’s ability to induce
maximum physiological effects. Although isoprena-
line had a high potency and high pharmacological
efficacy (Table 2), extensive interactions with b1-
receptors limited its usefulness because of its
potential to cause cardiovascular side effects.
Hence, in the 1960s more selective b2-agonists,
such as fenoterol, salbutamol and terbutaline,
were developed.Fenoterol
Fenoterol (Fig. 1) is a resorcinol derivative of
orciprenaline, with negligible a-receptor-stimulating
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although less so than salbutamol and, possibly,
terbutaline.54 Inhaled fenoterol produces superior
bronchoprotection compared with isoprenaline.54
Although the time to maximum effect is longer with
fenoterol, its duration of action (4–6h) is also longer
compared with isoprenaline (Table 2) and it has less
effect on heart rate.54 ln one early study, 20 of 22
patients with asthma receiving both fenoterol and
isoprenaline aerosol inhalers expressed a preference
for fenoterol.55Salbutamol
Salbutamol (albuterol), developed by modifying the
basic catechol nucleus common to the naturally
occurring adrenergic neurotransmitters adrenaline
and noradrenaline, was introduced in 1969. Salbu-
tamol is longer lasting than isoprenaline and
isoetharine because it is not broken down by
catechol O-methyltransferase.56 The salbutamol
molecule (Fig. 1) is hydrophilic and accesses the
b2-receptor directly from the aqueous extracellular
compartment. This results in a fast onset of action,
with effective bronchodilation occurring within
2–3min and peak bronchodilation within 15min of
inhalation.57 However, the molecule binds only
weakly to the receptor and quickly diffuses back
into the microcirculation. This accounts for its
short duration of action (4–6 h), similar to that of
fenoterol (Table 2).
Salbutamol has negligible a-receptor activity and
demonstrated a 4500-fold greater selectivity
between b2- and b1-receptors than any other
product previously available.58 Salbutamol thus
overcame many of the limitations of its predeces-
sors and quickly became the most widely used and
popular b2-agonist.Table 2 Summary of some pharmacological properties o
Affinity for Efficacy at Potency at
b2-receptor b2-adrenoceptors b2-adrenoce
ðKiÞ (nM) (relative to
isoprenaline
(relative to
isoprenaline
as 100%)
Isoprenaline 200 (100) (1.0)
Salbutamol 2500 86 0.55
Fenoterol — 100 —
Terbutaline — 65–85 —
Salmeterol 53 63 8.5
Formoterol 76 100 20.0
Data derived from Refs.25,58,78,141 (—denotes data not available)Levalbuterol (R-albuterol), a single isomer of
salbutamol, is currently available as a nebulised
solution in the USA. Several studies have compared
levalbuterol with salbutamol (racemic albuterol)
and suggest that use of the single isomer may
reduce hospitalisations,59 have fewer adverse
effects60 and provide similar bronchodilator effects
at a reduced dose.61 However, other studies have
indicated similar efficacy of the isomer and the
racemic form,62,63 echoed by the current interna-
tional guidelines on the management of asthma.64
Further development and evaluation of enantio-
mers may clarify whether there are significant
benefits to be obtained from single isomer forms of
b2-agonists.
Terbutaline
Terbutaline (Fig. 1) is a non-catecholamine b2-
agonist related to orciprenaline. It is also resistant
to degradation by catechol O-methyltransferase
because it contains a resorcinol group.65 lt was
specifically developed to relax the trachea without
affecting the cardiac muscle, and was first intro-
duced in 1970.66 Bronchodilation occurs rapidly
after inhalation and effects may persist for 4–6 h
(Table 2). Terbutaline is useful for as-needed
medication. A prodrug of terbutaline, oral bambu-
terol, is also an effective bronchodilator when
given orally, and has a longer duration of action
similar to that of salmeterol.67
Limitations of short-acting b2-agonists
Although terbutaline and salbutamol are very
widely used, they have a relatively short duration
of action. Whether taken by inhalation or by
mouth, the duration of bronchodilation achievedf selected b2-agonists.
Selectivity ratio Approximate Approximate
ptors (b2 : b1 receptors) onset of duration of
)
action (min) action
1:1 2–5 o20 min
1:1375 2–3 4–6 h
1:120 2–4 4–6 h
— 2–4 4–6 h
1:85 000 30 412 h
1:120 2–3 412 h
.
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4–6 h. Although this does not affect their usefulness
for as-needed medication, it does impose limita-
tions for patients who require continuing broncho-
dilator therapy to reverse airway narrowing and
long-term protection from bronchospasm, e.g.
patients with nocturnal asthma. The need for b2-
agonists with a longer duration of action was the
impetus for the development of formoterol and
salmeterol.
b2-agonists with long-acting properties
There are currently two inhaled b2-agonists with
durations of action in excess of 12 h, formoterol
and salmeterol. Each molecule was developed to
interact specifically with the b2-receptor. Their
profiles are best understood by considering their
different physicochemical properties in the micro-
environment of the b2-receptor, including the cell
membrane.
Formoterol
Formoterol (eformoterol in the UK) is a formani-
lide-substituted phenoethanolamine (Fig. 1) and
was synthesised as part of a series of molecules
systematically developed for increasing b2-recep-
tor selectivity and bronchodilator potency.68
Although originally developed for oral use, formo-
terol was subsequently found to have an extended
duration of action when taken by inhalation.69
When b2-agonists are inhaled, high topical
concentrations are instantly deposited on the
airway epithelia: concentrations of formoterolFigure 3 Diagrammatic representation of the diffusion m
Elsevier.71and salmeterol of 1mmol=l have been estimated in
the periciliary fluid of the bronchi after a single
inhalation.20 The molecules then diffuse across the
epithelium towards the airway smooth muscle.
Formoterol is moderately lipophilic (Kr½mem500 : 1)
70
and most of the inhaled dose that reaches the
smooth muscle layer is taken up into the cell
membranes. This forms a depot from which for-
moterol is thought to progressively leach out to
interact with the b2-receptors (Fig. 3). Formoterol
thus has a prolonged effect, causing bronchodilation
that lasts for more than 12h72,73 (Table 2). However,
sufficient numbers of molecules remain in the
aqueous phase outside the cells to allow immediate
interaction with b2-receptors and, therefore, a fast
onset of bronchodilation (within 1–3min).74 Hence,
formoterol acts as rapidly as salbutamol.75
Compared with salmeterol and salbutamol, for-
moterol is a full agonist at the b2-receptor and
results in more than 80% of maximal b2-receptor
activation.71 In terms of relaxing isolated human
bronchi, formoterol has been found to be 4100
times more potent than salmeterol and4300 times
more potent than salbutamol.76Salmeterol
Salmeterol is a saligen derivative of phenylethano-
lamine (Fig. 1) developed in the early 1980s and has
been available clinically since 1990. When the
molecule was designed, the head group of salbuta-
mol was used, taking advantage of this molecule’s
b2-agonist properties and minimal side-effect pro-
file on other adrenoceptors. The aliphatic side
chain was extended to interact with a theoreticalicrokinetic hypothesis. Reprinted with permission from
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prolong the action of the salmeterol molecule.68
The salmeterol side chain has a length of 17 (A;
which makes the molecule 410 000 times more
lipophilic than salbutamol.58 Salmeterol therefore
partitions rapidly (within 1min) into the outer
phospholipid monolayer of any cell membrane in its
vicinity (Kr½mem 22,500: 1), and appears to diffuse
laterally along the cell membranes, at approxi-
mately 2mm=s .77 However, to diffuse through the
tissue, from epithelium through the submucosa to
the bronchial smooth muscle, salmeterol has to
diffuse out of one cell membrane, to enter the
next, to continue its diffusion. Since most salme-
terol molecules are present in cell membranes, this
is a relatively slower process than that observed
with formoterol, thus explaining the slower onset
of action of salmeterol. Furthermore, little inter-
action with b2-receptors on the interstitium may
also contribute to the relatively slower onset of
action of salmeterol. Clinically, salmeterol does not
achieve its maximum effect until approximately
30min after inhalation, whereas formoterol, sal-
butamol and terbutaline reach clinically important
effects within 3min, and close to maximum effects
within 10–15min.57,73,75
The extended duration of action of salmeterol
has been explained by its long aliphatic side chain
acting via an exosite within the b2-recep-
tor.24,58,78,79 Although this could explain its
extended duration of action and the molecule’s
ability to ‘reassert’ its effect after multiple
wash-out cycles, other molecules (including
formoterol) also have this property of reassertion
without having long side chains. Consequently,
the exosite hypothesis is not universally ac-
cepted.20 Pre-treatment of airway smooth muscle
tissue with the pure aliphatic side chain of
salmeterol failed to block the long duration of
salmeterol, which should have occurred if the
anchored binding was the only mechanism for its
long duration of action.80
The plasmalemma diffusion microkinetic model,
outlined above for formoterol,21 also explains the
activity of salmeterol by its partitioning behaviour
into the plasmalemma lipid bilayer (Fig. 3).
Salmeterol does not appear to cross the membrane
to enter the cytoplasm, but rather remains in the
outermost monolayer, and slowly diffuses from the
membrane (t1=2 approx 25min at 25 1C).
77 This
mechanism alone, or together with the ‘anchored
binding theory’, explains the long duration of
action of salmeterol. This differs from formoterol,
for which long duration of effect is explained by a
depot of formoterol molecules in cell membranes in
the smooth muscle or in the tissue72,73 (Fig. 3).Compared with formoterol, salmeterol is a
partial agonist at the b2-receptor and therefore
does not result in maximal bronchodilation.70,81,82
Salmeterol is appropriate for use as a regular long-
acting b2-agonist, but not for rapid reversion of
airflow obstruction or for treatment of acute
symptoms of asthma.Current use of b2-agonists
Regular use and as-needed use
Since the importance of inflammation in causing
the symptoms of asthma was recognised, anti-
inflammatory drugs, particularly ICS, have been
recommended for first-line maintenance treat-
ment.83 Bronchodilators, such as the inhaled
short-acting b2-agonists salbutamol (200 or 400mg)
and terbutaline (0.5mg), are now regarded as
symptom-relieving drugs to be given on an ‘as-
needed’ basis.84 This change in usage, from a
regular four-times daily regimen (which, it was
thought, would ‘keep the airways open’) to use
only as needed, was catalysed by a study showing
that the regular use of the potent short-acting b2-
agonist fenoterol resulted in a significant deteriora-
tion of asthma control.85 This deterioration was
accompanied by a decline in lung function and
increased airway responsiveness,86 as well as more
exacerbations,85–87 despite concurrent use of ICS.
The regular use of salbutamol had become
widespread as standard practice, based in large
part on one very short study.88 ln this crossover
study with 1 week of treatment in each arm,
slightly higher evening PEF (measured after bronch-
odilator use) and less need for reliever salbutamol
(but overshadowed by eight puffs of regular
treatment each day) were regarded as benefits of
regular treatment. Extrapolation of regular use of
salbutamol to the more potent agent fenoterol
seems to have been a major reason for the
epidemic of asthma mortality experienced in New
Zealand from 1976 onwards. Subsequent work has
shown no advantage in patients taking salbutamol
on a regular basis over and above its use as
needed.89
On the other hand, studies with the longer-acting
b2-agonists formoterol ð12 mg delivered dose twice
daily) and salmeterol ð50mg twice daily) have
shown that both improve lung function and increase
overall asthma control when used regularly in
combination with ICS.84 ln particular, regular use
of these agents has been shown to reduce the ICS
dose requirement and hence the potential for easy
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increased incidence of oropharyngeal side effects
associated with prolonged high-dose ICS therapy.90
This is supported in part by a study in which 50%
reduction in ICS dose with concomitant salmeterol
therapy was well tolerated with no significant loss
of asthma control.91 However, that study also
showed that stopping ICS treatment altogether,
while continuing salmeterol therapy, resulted in a
significant ðPo0:001Þ increase in the number of
asthma exacerbations. This reinforces the view
that although long-acting b2-agonists have a ster-
oid-sparing effect when used in combination with
ICS, they do not show anti-inflammatory activity
and when used independently do not maintain as
good asthma control.Combination therapy with salmeterol
Addition of a long-acting b2-agonist to ICS (combi-
nation therapy) has been demonstrated in many
studies to be more effective in reducing asthma
symptoms and increasing lung function than in-
creasing the ICS dose alone. Studies in patients with
asthma who were symptomatic despite mainte-
nance treatment with beclomethasone and who
showed bronchodilator responsiveness, have de-
monstrated that, compared with an increased dose,
adding salmeterol to the existing dose of beclo-
methasone was preferable to increasing the dose of
steroid alone. With combination therapy, daytime
and night-time symptoms were better controlled,
morning and evening PEF rates were improved, and
diurnal variation and use of relief bronchodilator
medication were reduced.92,93
Patients initiated into maintenance treatment
with a combination of salmeterol and fluticasone
propionate were found to have greater improve-
ments in pulmonary function and symptom control
than those initiated on treatment with either
therapy alone.94 Equally, patients symptomatic
while receiving low-dose fluticasone propionate
ð100mgÞ achieved significantly greater improve-
ments in lung function and symptom control and
fewer exacerbations, when salmeterol was added
to their existing dose of steroid, compared with
patients whose dose of fluticasone propionate was
more than doubled without the addition of salme-
terol.95 However, a study by D’Urzo and collea-
gues96 demonstrated no additional benefit of
salmeterol on the number of severe exacerbations
in patients concomitantly taking optimal anti-
inflammatory treatments, although significant im-
provements in PEF, night-time awakenings and
reliever medication use were observed.The choice of fluticasone dose in such studies is
clearly important as a substantial proportion of the
therapeutic benefit can be achieved with a total
daily dose of 200mg=day:97 Although it is reasonable
to choose an optimal ICS dose, thus avoiding under
treatment, little additional benefit from higher
doses would be expected as such doses would be on
the plateau of the dose–response curve.Combination therapy with formoterol
The 12-month FACET (Formoterol And Corticoster-
oids Establishing Therapy) study was the first
investigation into asthma therapy that used reduc-
tion in the rates of severe and mild exacerbations
as the primary efficacy parameters.98 The study
demonstrated that adding formoterol to two
different doses of budesonide reduced rates of
severe and mild exacerbations per patient and
significantly ðPo0:05Þ improved symptom scores,
lung function and the need for short-acting b2-
agonists for relief medication compared with
increasing the dose of budesonide alone.98 When
formoterol was added to the lower dose of
budesonide ð100mg metered dose, twice daily),
severe and mild exacerbations were reduced by
26% and 40%, respectively; when the same dose of
formoterol was added to the higher dose of
budesonide ð400mg metered dose, twice daily),
severe and mild exacerbations were reduced by
63% and 62%, respectively. Severe and mild
exacerbations were reduced by 49% and 37%,
respectively, comparing budesonide 400 mg with
100mg twice daily without the addition of formo-
terol. Hence, the FACET study demonstrated re-
duced exacerbations with a higher dose of ICS,
greater than with the addition of a long-acting b2-
agonist, but the greatest benefits were seen when
the two were combined.98
Adding formoterol to ICS also appears to be at
least as effective in improving lung function and
controlling asthma symptoms as doubling the dose
of ICS. For example, when formoterol twice daily
was added to beclomethasone 500mg daily, the
increase in mean morning PEF and decreased use of
reliever medication was significantly ðPo0:01Þ
greater than for patients not taking formoterol
whose ICS dose was doubled.99
The 12-month OPTIMA (Oxis [formoterol] and
Pulmicort [budesonide] Turbuhalers In the Man-
agement of Asthma) study in patients with mild-to-
moderate asthma also demonstrated that adding
formoterol to maintenance treatment in patients
who remained symptomatic despite receiving a low
dose of ICS, reduced exacerbations and improved
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ICS dose.100 However, in steroid-naı¨ve patients,
adding formoterol to ICS was no more effective at
reducing exacerbations than ICS alone. The slight
increase in lung function seen with formoterol
represents the bronchodilator response of normal
airways and is not of clinical significance.
Current treatment guidelines
The use of combination therapy is now reflected in
treatment guidelines. For adults and children over
5 years old with moderate and severe persistent
asthma symptoms in whom control is not achieved
by low to moderate doses of ICS alone, addition of
b2-agonists with long-acting properties, such as
salmeterol or formoterol, to ICS is recommended as
preferable to increasing the dose of ICS
alone.4,5,64,82,83Safety of b2-agonists
Side effects of b2-agonists
Side effects of b2-agonists are greatest when the
drugs are administered orally or parenterally.84
Unwanted effects include muscle tremor, increases
in blood glucose and lactate, and decreases in
serum potassium and serum calcium.26 b2-agonists
can impact cardiac function (producing, for exam-
ple, palpitations, tachycardia and arrhythmias in
rare cases), which must be monitored. Some of
these side effects can be considered inevitable
considering the pharmacological actions of the
drugs and the widespread distribution of b2-
receptors. For example, tremor results from
stimulation of the b2-receptors in skeletal muscle,
while even the most selective drugs will have some
effect on b2-receptors in the heart.
56 However,
most pharmacologically predictable events appear
to be of little clinical significance in patients
receiving recommended doses. If the drug is given
by inhalation, many side effects are avoided as the
systemic load and thus the plasma concentration of
the drug is reduced.56 Patients with more severe
airway obstruction may be relatively protected
from unwanted side effects due to reduced lung
absorption.101
Tachyphylaxis to both the bronchoprotective
effect, and, to a lesser extent, the bronchodilator
activity, occurs with all b2-agonists
102,103 although
this can be attenuated with corticosteroid ther-
apy.104,105 The significance of such tachyphylaxis
has been much debated. Recent concerns havearisen over tolerance to regular long-acting b2-
agonist therapy and whether this reduces the
efficacy of rescue b2-agonists when used for rapid
relief of symptoms. While carefully designed
studies show reduced effectiveness of short-acting
b2-agonists in increasing lung function or in rever-
sing methacholine-induced bronchoconstriction,
studies in the emergency room have failed to show
any significant differences in response rates to
high-dose short-acting b-agonists as needed for the
treatment of acute asthma in patients receiving
long-acting b-agonist.106Increased mortality associated with b-
agonists
Between 1959 and 1966, the death rate in the UK
among patients aged 5–34 years with asthma
increased threefold, with similar patterns reported
elsewhere.107 Since asthma had rarely been fatal
before and no new environmental factors appeared
to be involved, concerns were raised about the use
of new medications, in particular pressurised
isoprenaline aerosols. These deaths were even-
tually linked to the use of a particularly strong
formulation of isoprenaline (isoprenaline forte: five
times stronger than the dose of isoprenaline
metered dose inhaler [MDI] used in other coun-
tries).107 The death rate decreased following wide-
spread publicity about possible overuse of this drug
and the importance of medical supervision. Iso-
prenaline was later superseded by more selective
b2-agonists, such as fenoterol and salbutamol.
However, fenoterol subsequently became linked
to a second epidemic of asthma mortality in New
Zealand in the late 1970s.
Fenoterol MDI was introduced into New Zealand
in April 1976—the same year that the second
epidemic began. Although making up less than 5%
of the MDI b2-agonist market in most countries,
fenoterol soon accounted for almost 30% of the
total MDI b2-agonist sales in New Zealand.
108
Fenoterol MDI was dispensed at 200 mg/inhalation
(compared with salbutamol at 100mg/inhalation)
and shows similar b2-receptor selectivity to salbu-
tamol. The somewhat greater magnitude and
duration of bronchodilation with fenoterol com-
pared with salbutamol may have led to a delay in
patients recognising the severity of an attack and
seeking medical help.109,110 Alternatively, it was
suggested that fenoterol was associated with
increased mortality by increasing cardiac adverse
events.108 Findings from case–control studies of
patients who died from asthma during the late
1970s and 1980s in New Zealand were consistent
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increased the risk of death in severe asth-
ma.108,111,112 A clinical study of regular b-agonist
therapy with two doses of fenoterol 0.2mg four
times daily, demonstrated a deleterious effect on
airway responsiveness, lung function, and clinical
control of asthma compared with as-needed
b2-agonist treatment.
85 This supports the hypoth-
esis that fenoterol may have increased asthma
severity and fuelled the epidemic of mortality.113
Time-trend data further supported this hypoth-
esis.114 Not only did the increased death rate from
asthma in New Zealand closely follow the introduc-
tion and use of fenoterol and decline after
restrictions on fenoterol, but hospital admissions
also declined abruptly. This strongly suggests that
the adverse effect of fenoterol was on asthma
severity and not cardiac toxicity. There was no
suggestion of a class effect of inhaled b2-agonists in
the epidemic and no evidence that the increased
death rate may have occurred because of under-
prescribing of ICS, or the influence of social factors,
such as unemployment.115
Increased mortality has also been associated with
long-acting b2-agonist therapy. In a recent study of
salmeterol in patients with asthma, a post-market-
ing clinical trial was halted early following the
discovery of a non-significant trend towards more
asthma-related deaths in patients taking salmeter-
ol.116 African-American patients (17% of study
population), especially those not maintained on
ICS, had a significantly higher risk of death. These
deaths led to a labelling change indicating caution
in the use of salmeterol in African American
patients.
The interpretation of studies relating to asthma
morbidity and mortality, and the associations with
potent or frequent use of inhaled short-acting b2-
agonists, has been much debated. Caution was
urged over the regular use of all inhaled b2-agonists
based on the study of regular fenoterol vs. as-
needed bronchodilator.85 Sears and Taylor113 pro-
posed the hypothesis that the increased morbidity
and mortality of asthma over the previous decade
was related to increased disease severity, as
evidenced by increased airway responsiveness
related to regular inhaled b2-agonist use. The
abrupt and striking decrease, not only in asthma
mortality but also in asthma-related hospital
admissions in New Zealand following the with-
drawal of fenoterol in 1990, implied a likely causal
relationship between fenoterol and asthma sever-
ity, rather than cardiac toxicity.2
A study commissioned by Boehringer Ingleheim,
the manufacturers of fenoterol, of death and near-
death events in Saskatchewan, Canada, and therelationship with use of asthma drugs, found an
odds ratio for death of 5.4/canister/month with
inhaled fenoterol and 2.4/canister/month with
salbutamol compared with the reference group of
patients with asthma who did not receive any b2-
agonist.117 Further analysis of this study revealed
that the risk of asthma death began to escalate
markedly at about 1.4 canisters/month of inhaled
b2-agonist.
118 Svedmyr and Lo¨fdahl84 argued that,
with the exception of nebulised and high-dose
fenoterol, no study has convincingly demonstrated
a connection between the use of inhaled b2-
agonists at recommended doses and an increase in
asthma deaths. A review of the literature on the
clinical experience with inhaled b2-agonists con-
cluded that these agents remain appropriate and
reliable treatments for patients with asthma.119
Nevertheless, the two mortality epidemics linked
with high-strength isoprenaline in the 1960s and
with fenoterol in the late 1970s, have made most
clinicians cautious in prescribing potent short-
acting b2-agonists regularly or frequently as relie-
ver therapy.Tolerance to b2-agonists
The development of tolerance to their bronchodi-
lator activity may be a concern with the prolonged
use of b2-agonists due to receptor downregulation
and desensitisation. Because of their longer dura-
tion of b2-receptor occupancy, formoterol and
salmeterol might be expected to induce even
greater tolerance than the short-acting b2-ago-
nists. However, while a decrease in morning lung
function (PEF) has been shown following regular
treatment with salbutamol, no tendency to develop
tolerance has been shown with salmeterol120,121 or
formoterol.122–124 Where some tolerance to b2-
agonists has been demonstrated in patients with
asthma who experienced severe attacks,125 this has
usually been easy to overcome by increasing the
dose slightly.84
Patients taking salmeterol both with ICS92 and
without ICS126 showed no evidence of reduced
bronchodilator efficacy over 6 months of study.
Equally, the FACET study found no evidence of
deterioration in the control of asthma, and
although there was an initial decrease in bronch-
odilator efficacy upon addition of formoterol, the
improvements in lung function were maintained at
a higher level than with ICS alone for 1 year,
showing no further evidence of tolerance (Fig. 4).98
On the other hand, many studies have found
evidence for tolerance to the bronchoprotective
effects of long-acting b2-agonists to allergen or
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Figure 4 Increase in FEV1 in patients taking formoterol 9mg delivered dose twice daily plus budesonide either low dose
(100mg twice daily) or high dose (400mg twice daily) compared with patients taking the same doses of budesonide
alone. Reprinted with permission, copyrightr 1997 Massachusetts Medical Society. All rights reserved.98
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noted by McFadden,119 even where a significant
decrease in protective effect was noted, protection
still remained greater for the drugs investigated
than with placebo and never fell below pre-
treatment baseline values.
Regular use of long-acting b2-agonists has,
however, been linked with tolerance to rapid-
acting b2-agonists. Several studies have reported
reduced efficacy of short-acting b2-agonists follow-
ing treatment with formoterol or salmeterol.127–129
The acute administration of a high dose of
corticosteroids has, however, been shown to
attenuate this effect.49,51,130 van der Woude
and colleagues128 indicated that both formoterol
and salmeterol reduced the effect of salbutamol
to a similar extent, whereas van Veen et al.129
showed higher tolerance with salmeterol and
Lee et al.53 demonstrated higher tolerance with
formoterol in similar studies comparing the two
long-acting b2-agonists. In contrast, Nelson et al.
131
and Korosec et al.106 reported no decrease
in efficacy of salbutamol following treatment
with salmeterol, demonstrating no clinically im-
portant tolerance. The interaction between
long- and short-acting b2-agonists may be asso-
ciated with prolonged receptor occupancy by long-
acting b2-agonists, preventing binding by other
b2-agonists.
130Long-term safety of b2-agonists
There is growing evidence that b2-agonists with
long-acting properties are safe and effective as an
add-on treatment option for patients with asthma
poorly controlled by low doses of ICS alone.
Improvements in symptoms do not appear to be
made at the expense of a worsening of underlying
control, and systemic adverse effects resulting
from prolonged use of high doses of corticosteroids
can be reduced.132Future developments in asthma care
b2-receptor gene polymorphisms
It is now known that there are subgroups of asthma
patients who experience bronchodilator desensiti-
sation related to specific polymorphisms of the b2-
receptor genes.133 However, while these subgroups
of patients may experience reduced benefit from
the use of formoterol or salmeterol on a regular
basis, there is no evidence that they would not
benefit from the rapid onset of formoterol (i.e. if
used as needed).44 Patients with certain b2-recep-
tor gene polymorphisms have demonstrated lower
airway responsiveness to inhaled salbutamol;40,41
however, reduced bronchoprotection was not evi-
dent in similar patients using formoterol.45
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the b2-receptor gene, discussed earlier, each with
different properties and resulting in different
responses to b2-agonist therapy, raises the future
possibility of asthma treatments being individually
tailored to match patient genotypes.32 In this
respect, it is significant that patients have been
identified who did not respond to salmeterol but
who still responded to formoterol.134–136Figure 5 Kaplan–Meier plot showing estimated probabil-
ity of remaining without severe exacerbation in patients
taking formoterol 4:5mg inhaled dose or inhaled terbuta-
line 0.5mg as needed. Reprinted with permission from
Elsevier.123b2-agonists in exercise-induced
bronchoconstriction
The long duration of action of formoterol and
salmeterol should make these drugs more effective
for protection against exercise-induced broncho-
constriction (EIB) than the traditional, short-acting
b2-agonists, such as terbutaline and salbutamol.
Salmeterol (50 mg single dose) has been shown to
protect against EIB for more than 12 h;137,138
although the protective effect of salmeterol does
decrease when the drug is taken regularly.139
Similarly, single doses of formoterol delivered by
Turbuhaler (6 and 12mg) gave significantly ðPo0:05Þ
better and longer protection against EIB in adults140
and children141 compared with terbutaline 0.5mg.
Formoterol had about three-times longer duration
of effect than the short-acting bronchodilators
normally used to protect against EIB.141
Regular use of inhaled b2-agonists can result in a
reduction in the protective effect that they offer
against bronchoconstrictor stimuli. In one clinical
trial, for example, patients with EIB received either
formoterol or placebo twice daily for 4 weeks and
performed two cycle ergometer tests, 30min
apart, on days 1, 14 and 28; a dose of formoterol
was taken 30min before the second test. Signifi-
cant tolerance to the protective effect of formo-
terol was evident in the formoterol patients, but
not in the placebo patients, at days 14 and 28
(P ¼ 0:012 for both occasions).142 This is echoed in
a meta analysis of corticosteroid-treated patients
with asthma.50 In patients with the Arg16 poly-
morphism, 1–2 weeks of treatment with formoterol
was less effective than placebo. A study of patients
with EIB compared the effects of salmeterol with
the leukotriene receptor agonist montelukast.143
This study demonstrated tolerance to the protec-
tive effect of salmeterol but not to montelukast
over an 8-week period. Tolerance, however, is a
class effect that is shared by all b2-agonists and,
although the bronchoprotective effect is slightly
reduced with regular dosing, a clinically significant
level of bronchoprotection remains in the majority
of patients.b2-agonists used as needed
Although the b2-agonists with long-acting proper-
ties, formoterol and salmeterol, are playing an
increasing role in combination with ICS in main-
tenance treatment of asthma, a further develop-
ment is the use of fast-acting formoterol for use as
needed for symptom relief.
Formoterol given by Turbuhaler has as rapid an
onset of action as salbutamol administered by
pressurised MDI (pMDI).75 Studies have shown that
formoterol has a wide safety margin when used as
needed in addition to maintenance dosing. For-
moterol was well tolerated at daily doses corre-
sponding to 90mg delivered dose in patients with
stable chronic asthma and without concomitant
ischaemic heart disease,144 and in patients with
acute bronchoconstriction in an emergency room
setting.145
A randomised, double-blind, parallel-group, 3-
month study compared formoterol 6mg with terbu-
taline 0.5mg (both delivered by Turbuhaler) taken
as needed.124 ln this study, patients had moderate-
to-severe asthma requiring as-needed medication
despite taking an ICS. Patients given formoterol as
reliever medication experienced a significantly
ðP ¼ 0:013Þ longer time to first severe exacerbation
(Fig. 5), had greater improvement in lung function
and took fewer inhalations of this as-needed
medication, compared with patients given terbuta-
line. Both treatments were well tolerated, with no
statistically significant differences between the
two treatment groups in electrocardiographic find-
ings, serum potassium concentration or adverse
events.
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needed with salbutamol all demonstrated greater
improvement in asthma control with formoter-
ol.146–148 A recently published, 6-month, real-life
study comparing formoterol and salbutamol as
reliever medication provided further evidence of
the efficacy of formoterol as needed, with a
significant ðPo0:001Þ reduction in the risk of
asthma exacerbations compared with salbuta-
mol.149 This study was powered primarily for safety
outcomes ðn ¼ 18; 132Þ and confirmed that formo-
terol used as needed had a safety profile similar to
that of salbutamol.
There is thus strong evidence that formoterol’s
unique combination of long duration and fast onset
makes it suitable not only for regular maintenance
treatment in asthma (in combination with ICS) but
also for use as needed. Formoterol has recently
gained FDA approval for use as a rescue medica-
tion. This is reflected in the current Global
Initiative for Asthma (GINA) guidelines, which has
revised its classification of b2-agonists to rapid-
acting and/or long-acting.64 ln the clinical setting,
the rapid onset of action of formoterol enabling as-
needed use may become equally as important as its
property of a long duration of action.Can b2-agonists be used as monotherapy?
Neither short-acting nor long-acting b2-agonists are
currently recommended as monotherapy in pa-
tients with persistent asthma because of a per-
ceived lack of anti-inflammatory activity.4,5,64,83
Most studies have found no convincing evidence of
reduction in inflammatory cell infiltrates in airway
walls or in secretions following use of these agents.
Some studies have suggested that treatment with
formoterol150 and with salmeterol151 can reduce
some markers of airway inflammation in patients
with asthma and have suggested the intriguing
possibility that these drugs may, in fact, be capable
of independent anti-inflammatory action. Likewise,
recent research has suggested that there may be
interactions between long-acting b2-agonists and
corticosteroids at the cellular levels.152 More
research is needed to determine whether this is
relevant to the clinical use of these b2-agonists.Conclusions
Whether used prophylactically, as needed, or
regularly in combination with ICS, b2-agonists have
played a significant role in the treatment of asthma
since they were first introduced nearly half a
century ago. Although each era has had its drugof choice, the b2-agonists have shown a continuous
evolution, with compounds offering progressively
increasing selectivity, combined with faster onset
and longer duration of action. This is reflected in
the most recent update of the GINA guidelines,
which has reclassified the traditional short-and
long-acting b2-agonists into rapid-and/or long-act-
ing b2-agonists.
64
Although salbutamol is widely used as reliever
medication for acute bronchoconstriction, its short
duration of action makes it less appropriate for
regular use and unsuitable for relieving night-time
symptoms. Drugs with a longer duration of action,
such as salmeterol and formoterol, are more
appropriate in these circumstances. The combina-
tion of the rapid onset and long duration of
formoterol provides prompt and long-lasting symp-
tom relief for patients, combined with fewer
exacerbations. Further research is needed to assess
the benefits that this agent may have in terms of
patient quality of life and the economic burden of
the disease.References
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